Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Sci., St. Jude settle patent suits

This article was originally published in The Gray Sheet

Executive Summary

Both firms appear to benefit from a settlement that resolves four patent disputes related to the firms' cardiac rhythm management and neuromodulation devices. According to the July 31 announcement, the companies also have reached an accord to limit legal parameters for two additional suits, one of which dates back to 1996 (1"The Gray Sheet" Feb. 18, 2002, In Brief). The agreement bars Boston Scientific from pursuing lost profits and caps royalties at 3% of revenue from sales found to have infringed the patent in question. The companies agreed to cross-license certain of their cardiac rhythm management and neuromodulation patents. St. Jude describes the cross-license agreements as "worldwide" and "royalty free" in a filing with the Securities & Exchange Commission...

You may also be interested in...

Guidant v. St. Jude

Overturned $140 mil. implantable cardiac defibrillator patent infringement damage award to Guidant will likely be appealed, according to St. Jude. Filed by Guidant in November 1996 in Indianapolis federal court, the complaint currently focuses on two Guidant ICD patents ('472 and '288). Judge David Hamilton ruled Feb. 13 that "both patents are invalid," St. Jude says. A jury awarded Guidant the damages in July 2001, after finding that St. Jude infringed the '472 patent, which expired March 4, but that it did not infringe the '288 patent; both had been ruled valid (1"The Gray Sheet" July 9, 2001, In Brief)...

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts